AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 23420231
Drug: Acupuncture plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture plus rescue medication (cetirizine)
Trial: 23420231
Drug: Sham acupuncture
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham acupuncture plus rescue medication (RM)
Trial: 15557392
Drug: Progressive increases
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Progressive increases in salt intake from 10 to 250 mmol/d by a daily amount of 50 mmol
Trial: 10372794
Drug: High intensity
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High intensity cognitive‐behavioral therapy
Trial: 10372794
Drug: Low intensity
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low intensity therapy
Trial: 1816196
Drug: norfloxacin 400
RxNorm normalized name: norfloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: norfloxacin 400 mg bid for 10 days
Trial: 1816196
Drug: amoxycillin 500
RxNorm normalized name: Amoxycillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: amoxycillin 500 mg bid plus tinidazole 500 mg bid for 15 days
Trial: 1816196
Drug: colloidal bismuth
RxNorm normalized name: Colloidal bismuth subcitrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: colloidal bismuth subcitrate (CBS) 240 mg bid for 4 weeks
Trial: 27988427
Drug: CBT-SAD (social
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBT-SAD (social anxiety specific cognitive behavioral therapy)
Trial: 27988427
Drug: CBT-GEN (generic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBT-GEN (generic cognitive behavioral therapy)
Trial: 23620930
Drug: Flying needling
RxNorm normalized name: house fly extract
DrugBank: Musca domestica (DB10688)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flying needling therapy
Trial: 15704053
Drug: Acarbose 100
RxNorm normalized name: acarbose 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acarbose 100 mg 3 times daily
Trial: 8411611
Drug: Ranitidine 150
RxNorm normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ranitidine 150 mg twice a day
Trial: 31914075
Drug: Mosapride citrate
RxNorm normalized name: mosapride citrate
DrugBank: Mosapride (DB11675)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mosapride citrate with a split-dose of PEG plus ascorbic acid
Trial: 28573932
Drug: Low-intensity warfarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-intensity warfarin (INR maintained at 1.5 to 2.0) in group A
Trial: 28573932
Drug: Standard-intensity warfarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-intensity warfarin (INR maintained at 2.0 to 2.5) in group B
Trial: 17598506
Drug: Prophylactic vaccines
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic vaccines for primary prevention
Trial: 15076015
Drug: Temazepam 20
RxNorm normalized name: temazepam 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temazepam 20 mg for 2 weeks
Trial: 12705512
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg slow-release caffeine
Trial: 3276409
Drug: Intravenous streptokinase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous streptokinase (IVSK)
Trial: 26320523
Drug: Diphenhydramine 50
RxNorm normalized name: diphenhydrAMINE 50 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diphenhydramine 50 mg intravenously + Metoclopramide 10 mg intravenously
Trial: 26320523
Drug: Placebo +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo + Metoclopramide 10 mg intravenously
Trial: 18951860
Drug: Lidocaine patch
RxNorm normalized name: LIDOCAINE 40 mg TOPICAL PATCH [Lidocaine Patch]
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine patch (LP) applied on the anterior abdominal wall
Trial: 18951860
Drug: No lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No lidocaine patch applied
Trial: 16128595
Drug: 50 mg/mL
RxNorm normalized name: urea 50 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg/mL oral suspension
Trial: 16128595
Drug: 200mg tablets
RxNorm normalized name: allopurinol 200 MG / lesinurad 200 MG [Duzallo]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200mg tablets
Trial: 16128595
Drug: 800mg tablets
RxNorm normalized name: piracetam 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800mg tablets (reference)
Trial: 2571114
Drug: Dipivefrin hydrochloride
RxNorm normalized name: Dipivefrin Hydrochloride
DrugBank: Dipivefrin (DB00449)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dipivefrin hydrochloride 0.1% twice daily
Trial: 31960907
Drug: ICSI (Intracytoplasmic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICSI (Intracytoplasmic Sperm Injection)
Trial: 31654580
Drug: Bar implant
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bar implant overdentures (BOD)
Trial: 31654580
Drug: Resilient telescopic
RxNorm normalized name: dimethicone
DrugBank: Dimethicone (DB11074)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Resilient telescopic implant overdentures (TOD)
Trial: 31654580
Drug: Stud implant
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Stud implant overdentures (SOD)
Trial: 31586772
Drug: Melatonin 25
RxNorm normalized name: calcium phosphate/melatonin 250 mg-1.5 mg ORAL TABLET,CHEWABLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin 25 mg administered 1 hour before bedtime for 12 weeks
Trial: 31586772
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered 1 hour before bedtime for 12 weeks
Trial: 28342282
Drug: Immediate-release tacrolimus
RxNorm normalized name: tacrolimus Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release tacrolimus (IR-TAC)
Trial: 28342282
Drug: Extended-release tacrolimus
RxNorm normalized name: tacrolimus Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release tacrolimus (ER-TAC)
Trial: 21777634
Drug: Low viscous
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low viscous alginate fibre‐based preloads of 3% concentration (500 ml volume) three times a day
Trial: 17980952
Drug: Isosorbide mononitrate
RxNorm normalized name: Isosorbide Mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide mononitrate (ISMN) vaginal gel 80 mg
Trial: 17980952
Drug: Misoprostol vaginal
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Misoprostol vaginal gel 200 microg
Trial: 16894289
Drug: Combined-modality therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined-modality therapy (chemotherapy + radiotherapy)
Trial: 16894289
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy including gemcitabine
Trial: 16894289
Drug: Positron emission
RxNorm normalized name: propofol lipid emulsion Injection [Propoven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Positron emission tomography after one or two cycles of chemotherapy
Trial: 12660125
Drug: Chlorhexidine-based product
RxNorm normalized name: chlorhexidine Dental Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorhexidine-based product (0.3% concentration); rinsed three times a day for 30s from the beginning of chemotherapy until the end of leukopenia
Trial: 12660125
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (amine-stannous fluoride combination); rinsed three times a day for 30s from the beginning of chemotherapy until the end of leukopenia
Trial: 12660125
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (amine-stannous fluoride combination); separate analysis for patients with <1000 leucocytes/microL for a minimum of three days
Trial: 1469516
Drug: Liquid supplement
RxNorm normalized name: Clear liquid supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid supplement (LS)
Trial: 29468748
Drug: Test diet
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test diet (0.8 g protein kg‐1 body weight: 35% animal proteins, 35% soy protein, 30% vegetable proteins)
Trial: 18277214
Drug: Hemiplegia rehabilitation
RxNorm normalized name: GLUTATHIONE 12.5 g in 100 mL ORAL LIQUID [K2LTS Brain Rehabilitation]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hemiplegia rehabilitation program with analgesic and calcitonin therapy, elevation, range of movement therapy, and contrast baths.
Trial: 18277214
Drug: Hemiplegia rehabilitation
RxNorm normalized name: GLUTATHIONE 12.5 g in 100 mL ORAL LIQUID [K2LTS Brain Rehabilitation]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hemiplegia rehabilitation program without additional therapies (control group).
Trial: 1435930
Drug: Amoxicillin for
RxNorm normalized name: Amoxicillin for Oral Suspension
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicillin for 10 days
Trial: 8653989
Drug: Phenobarbital (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenobarbital (100 mg/day for 16 days)
Trial: 29183956
Drug: G-formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-formula
Trial: 20855823
Drug: mGEMOX (gemcitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mGEMOX (gemcitabine 900 mg/m2 and oxaliplatin 80 mg/m2 IV infusion on days 1 and 8 every 3 weeks for maximum of six cycles)
Trial: 20855823
Drug: FUFA (fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FUFA (fluorouracil 425 mg/m2 and folinic acid 20 mg/m2 IV bolus weekly for 30 weeks)
Trial: 17912635
Drug: Letrozole 2.5
RxNorm normalized name: letrozole 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Letrozole 2.5 mg once daily for 5 years
Trial: 16376645
Drug: No antioxidant
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antioxidant supplements
Trial: 11568777
Drug: Continuous combined
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous combined hormone replacement therapy (ccHRT)
Trial: 10729965
Drug: Exercise in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise in combination with manual lymph drainage
Trial: 9127079
Drug: Intra-articular instillation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular instillation of 20 mL bupivacaine (0.25%) and local infiltration of 20 mL bupivacaine (0.5%)
Trial: 9127079
Drug: Saline solution
RxNorm normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline solution injection
Trial: 1436589
Drug: Defibrotide, 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Defibrotide, 400 mg b.i.d. i.m.
Trial: 1436589
Drug: Heparin calcium,
RxNorm normalized name: heparin calcium,porcine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin calcium, 5000 IU b.i.d. s.c.
Trial: 3466089
Drug: Aminoglycoside solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aminoglycoside solution
Trial: 3466089
Drug: Oral antianaerobic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral antianaerobic clindamycin
Trial: 30922377
Drug: Calcitriol 0.5
RxNorm normalized name: CALCITRIOL 0.5MCG CAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcitriol 0.5 mcg daily for three months
Trial: 30922377
Drug: Cholecalciferol 1000
RxNorm normalized name: cholecalciferol 1000 UNT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholecalciferol 1000 IU daily for three months
Trial: 30371299
Drug: Fenofibrate 145
RxNorm normalized name: fenofibrate 145 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenofibrate 145 mg/d for 24 weeks
Trial: 25440794
Drug: ALDH(br) cells
RxNorm normalized name: Respa-BR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALDH(br) cells delivered by direct intramuscular injections
Trial: 18958560
Drug: 80 mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg/m2 paclitaxel administered weekly
Trial: 15908042
Drug: Neo-adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neo-adjuvant chemotherapy (mitomycin, ifosfamide and cisplatin (MIC) or mitomycin, vinblastine and cisplatin (MVP)) followed by surgery (CT-S)
Trial: 11796917
Drug: Maintenance chemotherapy
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance chemotherapy post-ASCT
Trial: 10615229
Drug: Docetaxel (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel (100 mg/m2 every 3 weeks, n = 143)
Trial: 10615229
Drug: Sequential methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Sequential methotrexate and 5-fluorouracil (MF; 200 mg/m2 and 600 mg/m2 every 3 weeks, n = 139)
Trial: 7532395
Drug: Krypton laser
RxNorm normalized name: krypton (81mKr) gas
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Krypton laser treatment covering the foveal side with a narrow (< or = 100 microns) border of treatment to adjacent uninvolved retina.
Trial: 7532395
Drug: Krypton laser
RxNorm normalized name: krypton (81mKr) gas
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Krypton laser treatment with either some of the foveal side of the lesion left untreated or a wide border of treatment on the foveal side.
Trial: 7532395
Drug: Krypton laser
RxNorm normalized name: krypton (81mKr) gas
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Krypton laser treatment in eyes with neovascular lesions 200 to 500 microns from the center of the foveal avascular zone.
Trial: 7532395
Drug: Krypton laser
RxNorm normalized name: krypton (81mKr) gas
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Krypton laser treatment in eyes with lesions in either distance category in the Age‐Related Macular Degeneration Study.
Trial: 31414974
Drug: Sufficient 25(OH)D
RxNorm normalized name: 1α,25(OH)2D3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufficient 25(OH)D levels (30-100 ng/mL)
Trial: 31414974
Drug: Active vitiligo
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active vitiligo (associated with 25(OH)D deficiency ≤20 ng/mL)
Trial: 31414974
Drug: Active vitiligo
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active vitiligo (associated with 25(OH)D insufficiency 21-29 ng/mL)
Trial: 31414974
Drug: Stable vitiligo
RxNorm normalized name: Heat stable ricin vaccine
DrugBank: Heat stable ricin vaccine (DB18477)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stable vitiligo (associated with sufficient 25(OH)D levels 30-100 ng/mL)
Trial: 20609546
Drug: Entertainment-based decision
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Entertainment-based decision aid for breast cancer treatment along with usual care
Trial: 17878636
Drug: 50/50 premixed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50/50 premixed insulin lispro twice-daily
Trial: 17878636
Drug: premixed human
RxNorm normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: premixed human insulin (control group)
Trial: 15520061
Drug: Intravenous vinorelbine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous vinorelbine (VRL) 30 mg/m2 on days 1 and 8 every 3 weeks plus hydrocortisone 40 mg/day
Trial: 15520061
Drug: Intravenous vinorelbine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous vinorelbine (VRL) plus hydrocortisone
Trial: 3381992
Drug: 0.5 g
RxNorm normalized name: Gelatin Capsules, 10.5 gr
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 g dipyrone
Trial: 3381992
Drug: 1.0 g
RxNorm normalized name: IODINE 11.0 g in 1 L TOPICAL SOLUTION [T.D.]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 g dipyrone
Trial: 3381992
Drug: 1.5 g
RxNorm normalized name: Vaporizer Vicks 1.5 gal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 g dipyrone
Trial: 3381992
Drug: 2.0 g
RxNorm normalized name: Fifty50 2.0 Glucose Meter
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.0 g dipyrone
Trial: 31780037
Drug: Peppermint gel
RxNorm normalized name: Peppermint
DrugBank: Peppermint (DB10984)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peppermint gel applied three times a day for up to 14 days
Trial: 25586335
Drug: Peak CK‐MB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peak CK‐MB ≥300 IU/L
Trial: 21969009
Drug: Amlodipine (2.5-10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine (2.5-10 mg/d)
Trial: 21969009
Drug: Lisinopril (10-40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril (10-40 mg/d)
Trial: 18240352
Drug: Psychological intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Psychological intervention and medication
Trial: 16538423
Drug: Infrared LED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infrared LED treatment (160 mW, 6 min, energy density 3.2 J/cm²)
Trial: 11033843
Drug: BALF‐IL‐12 in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BALF‐IL‐12 in sarcoidosis patients (41.3 +/- 43.9 pg/ml)
Trial: 11033843
Drug: BALF‐IL‐12 in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BALF‐IL‐12 in patients with active disease (71.3 +/- 54.3 pg/ml)
Trial: 11033843
Drug: AM of
RxNorm normalized name: Balsam of Peru
DrugBank: Balsam of Peru (DB11482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AM of sarcoidosis (133 +/- 177 pg/ml)
Trial: 1470243
Drug: 20% albumin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20% albumin solution plus crystalline infusion fluids
Trial: 1470243
Drug: Crystalline infusion
RxNorm normalized name: Mesembryanthemum crystallinum whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crystalline infusion fluids (control group)
Trial: 19625715
Drug: Vi vaccine
RxNorm normalized name: TYPHIM Vi VACCINE INJ SYRINGE 0.5ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vi vaccine
Trial: 25018097
Drug: Control (Hepatitis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (Hepatitis A vaccine)
Trial: 28873320
Drug: Rhodiola rosea
RxNorm normalized name: RHODIOLA ROSEA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rhodiola rosea (RR) - SHR group (n = 10) ingested standardized extract SHR-5 (432 mg daily)
Trial: 29786343
Drug: Liquid wound
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid wound dressing (treatment group)
Trial: 24842866
Drug: Weekly cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly cisplatin (40 mg/m(2))
Trial: 24842866
Drug: 3-weekly cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3-weekly cisplatin (100 mg/m(2))
Trial: 22872200
Drug: Topical 1.5%
RxNorm normalized name: phenol topical 1.5% topical liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 1.5% azithromycin twice a day for three days
Trial: 22872200
Drug: Topical 1.5%
RxNorm normalized name: phenol topical 1.5% topical liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 1.5% azithromycin twice a day for three days then at bedtime for the rest of the month
Trial: 20497146
Drug: Esomeprazole 10
RxNorm normalized name: esomeprazole 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole 10 mg od for 4 weeks
Trial: 20497146
Drug: Esomeprazole 40
RxNorm normalized name: esomeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole 40 mg od for 4 weeks
Trial: 6383113
Drug: Aminophylline (60-120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aminophylline (60-120 mg)
Trial: 25560711
Drug: Valganciclovir (900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valganciclovir (900 mg/d)
Trial: 25560711
Drug: Placebo (preemptive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (preemptive therapy)
Trial: 17051503
Drug: Ritonavir-boosted comparator
RxNorm normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ritonavir-boosted comparator protease inhibitor (CPI/r)
Trial: 11340106
Drug: Beta-carotene capsules
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-carotene capsules (6 mg daily for 60 days)
Trial: 11340106
Drug: Puréed papaya
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Puréed papaya (650 g daily for 60 days)
Trial: 11340106
Drug: Grated carrots
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grated carrots (100 g daily for 60 days)
Trial: 3305590
Drug: Topical folate
RxNorm normalized name: folate
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical folate (2 daily applications)
Trial: 3305590
Drug: Systemic folate
RxNorm normalized name: folate
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Systemic folate (2 daily doses)
Trial: 24727022
Drug: MK-5172 (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-5172 (100 mg) with peginterferon and ribavirin
Trial: 24727022
Drug: MK-5172 (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-5172 (200 mg) with peginterferon and ribavirin
Trial: 24727022
Drug: MK-5172 (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-5172 (400 mg) with peginterferon and ribavirin
Trial: 24727022
Drug: MK-5172 (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-5172 (800 mg) with peginterferon and ribavirin